Breakthrough in Cancer Therapy: Artificial NK-EVs Show Potent Anti-Tumor Efficacy

Strategic Insights -

Researchers at the Shanghai University of Traditional Chinese Medicine have made a significant advancement in cancer therapy by developing artificial NK-EVs, which demonstrate superior scalability and bioactivity compared to natural EVs. According to the study, these artificial EVs can induce 70% cytotoxicity in lung cancer cells, trigger apoptosis, and restore degranulation capacity in cryopreserved NK cells. Furthermore, the artificial EVs have shown high biocompatibility and efficacy against non-small cell lung cancer (NSCLC) in murine models.

Key Takeaways:

  • The study developed artificial NK-EVs (NK-aEVs) through extrusion, which exhibit superior scalability and bioactivity compared to natural NK-EVs (NK-nEVs).
  • NK-aEVs can induce 70% cytotoxicity in lung cancer cells (A549, H1299, H460) at 200 mg/mL, trigger apoptosis, and restore degranulation capacity in cryopreserved NK cells.
  • In murine models, intratumoral NK-aEVs suppressed LLC and MC38 tumor growth by 60% without systemic toxicity.
  • NK-aEVs remodeled the tumor microenvironment by enhancing infiltration of CD8+ T/NK cells while reducing splenic immunosuppressive macrophages and myeloid-derived suppressor cells.
  • The study establishes a scalable platform for EV-based immunotherapy, overcoming production and functional constraints of natural EVs.
  • The artificial EVs have translational potential for modulating antitumor immunity and may be a promising approach for cancer treatment.

Statistics:

  • 70% cytotoxicity in lung cancer cells (A549, H1299, H460) at 200 mg/mL
  • 60% suppression of LLC and MC38 tumor growth in murine models
  • High biocompatibility and efficacy against NSCLC in murine models
  • A scalable platform for EV-based immunotherapy has been established

Sources:

  • Zhou, X., et al. (2025). NK cell-derived artificial extracellular vesicles elicit potent anti-tumor efficacy and tumor microenvironment reprogramming capability. Cancer Nanotechnology, 16(1), 1-21. DOI: 10.1186/s12645-025-00328-z
  • Shanghai University of Traditional Chinese Medicine.
  • National Natural Science Foundation of China.
  • Natural Science Foundation of Shanghai.